股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君圣泰医药（於開曼群島註冊成立的有限公司） 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02511 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | 本月底法定/註冊股本總額： USD 1 ...

智通财经APP讯，君圣泰医药-B(02511)发布公告，任命Filip Surmont博士为首席医学官，全面负责公司 的医学战略、临床开发及相关医学事务，助力公司核心管线在心肾代谢系统疾病(CKM)领域的研发进展 与价值提升。 ...

君圣泰医药-B(02511)发布公告，任命Filip Surmont博士为首席医学官，全面负责公司的医学战略、临床 开发及相关医学事务，助力公司核心管线在心肾代谢系统疾病(CKM)领域的研发进展与价值提升。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 君聖泰醫藥任命Filip Surmont博士為首席醫學官， 強化心腎代謝系統疾病(CKM)佈局 Filip Surmont博士職業生涯成就卓著。他助力達格列淨成為重磅暢銷藥物；也曾 在中國主導「ACT on HF」項目，成功讓20萬名心衰患者受益於指南推薦的標準 治療；他首創的哮喘「抗炎緩解劑(AIR)」治療策略，影響了全球約5000萬名患 者，並推動了國際治療指南的更新。作為國際權威醫學專家，Filip Surmont博 士長期深耕代謝及心血管相關疾病研究並積累了深厚學術聲望，多項研究發表 於《The Lancet Diabetes & Endocrinology》、《Journal of the American College of Cardiology》等頂級期刊。在職業生涯早期，Filip Surmont博士曾為奧運級運動員 提供醫療服務。Filip Surmont博士擁有比利時根特大學醫學博 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君圣泰医药（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02511 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100, ...

Core Viewpoint - Junshengtai Pharmaceutical is leveraging innovative molecules derived from natural products to address metabolic diseases, emphasizing a patient-centered approach to meet unmet clinical needs [2][3]. Group 1: Company Overview - Junshengtai Pharmaceutical was founded by Liu Liping in 2011, focusing on the research and development of drugs for metabolic diseases [3]. - The company aims to explore the potential of natural products in drug development, moving away from traditional methods of producing generic drugs [3]. Group 2: Product Development - The company has developed a novel molecular entity, HTD1801, by combining berberine from traditional Chinese medicine and ursodeoxycholic acid, targeting multiple pathways for treating various metabolic diseases [2][4]. - HTD1801 has shown potential in activating AMPK, improving glucose uptake, and reducing chronic inflammation, which are critical for managing metabolic disorders [4]. Group 3: Clinical Trials and Applications - Junshengtai Pharmaceutical has initiated two Phase 3 clinical trials for HTD1801 in Chinese patients with Type 2 Diabetes Mellitus (T2DM), achieving primary and multiple secondary efficacy endpoints [5]. - The company plans to submit a new drug application for HTD1801 for T2DM treatment and has identified chronic kidney disease (CKD) as an additional indication [5][6]. Group 4: Future Prospects - HTD1801 is expected to expand its indications, with ongoing research into its effects on CKD and potential combination therapies with GLP-1 receptor agonists for obesity management [6]. - The company aims to position HTD1801 as a foundational treatment in the cardiovascular-kidney-metabolic (CKM) field, providing comprehensive health solutions for patients [6]. Group 5: Innovation and Challenges - Liu Liping likens the process of developing innovative drugs to climbing Mount Everest, highlighting the challenges faced in combining natural molecules into a new compound [7]. - The company emphasizes a focus on breakthrough innovations and overcoming obstacles in drug development, reflecting the broader trends in China's pharmaceutical industry [7].

HighTide Therapeutics, Inc. 君聖泰醫藥 （於開曼群島註冊成立的有限公司） 股份代號：2511 HighTide Therapeutics, Inc. （「本公司」） 提名委員會職權範圍 1 釋義 高級管理層指行政總裁、首席財務官、首席運營官、首席開發官及本公司任 何其他高級職員，其薪酬待遇或建議薪酬待遇較任何由董事會委任的高級職 員優厚；及任何其他由薪酬委員會釐定的本公司僱員。 股東指本公司的股東。 聯交所指香港聯合交易所有限公司。 1. 就本職權範圍（「職權範圍」）而言： 董事會指本公司的董事會。 首席財務官指董事會不時委任負責財務管理的本公司高級人員。 公司秘書指本公司的任何一名聯席公司秘書。 董事指董事會成員。 本集團指本公司及其於有關時期的附屬公司和聯營公司；或按文義所指，於 本公司成為其當前附屬公司和聯營公司的控股公司前的期間，本公司當前的 附屬公司和聯營公司或其當前附屬公司和聯營公司或（視情況而定）其前身所 營運的企業。 上市規則指香港聯合交易所有限公司證券上市規則（經不時修訂）。 提名委員會指根據本職權範圍第2條通過董事會的決議案設立的提名委員會。 成立 2. 提名委 ...

Group 1 - The "Annual Growth Value Award" recognizes companies with significant growth potential in the capital market, emphasizing the importance of continuous growth for sustainable development [1][2] - The award selection process involves quantitative data analysis and expert review to identify companies that are proactive and committed to expansion [1] - The event highlighted ten companies that received the "Annual Growth Value Award," including 比优集团 (Biyou Group), 地平线机器人-W (Horizon Robotics-W), and others, listed in alphabetical order [1] Group 2 - The "Golden Grid Award" aims to create a valuable reference list of listed companies and unicorns, covering all companies listed on major exchanges such as the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, and others [2] - The initiative reflects a global perspective with a focus on investment opportunities in China [2]

Group 1 - The commercialization process of the core product HTD1801 is expected to accelerate within the year, with the NDA stage anticipated by the end of 2025 [1] - The company forecasts revenues of 0 million, 0 million, and 2.53 billion for the years 2025, 2026, and 2027 respectively [1] - A target price of 5.78 HKD per share is set for the next six months, with an initial "recommend" investment rating [1] Group 2 - HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator, granted two Fast Track designations by the FDA [2] - The product operates through a unique dual mechanism, aiming to treat cardiovascular and metabolic diseases comprehensively, showing significant efficacy in improving blood glucose metabolism and other health markers [2] - Clinical trial data indicates HTD1801 can significantly reduce HbA1c levels by -1.1% to -1.3%, outperforming the leading drug Dapagliflozin in achieving ideal HbA1c control [2] Group 3 - HTD1801 shows potential in chronic kidney disease (CKD) treatment, with clinical studies indicating it can improve eGFR levels in early-stage patients [3] - The drug demonstrated a significant improvement in eGFR compared to placebo in patients with mild kidney function impairment [3] - HTD1801 may also have a trend of reducing eGFR in patients with high renal filtration [3]

Core Viewpoint - The commercialization process of the core product HTD1801 is expected to accelerate within the year, with positive Phase III trial data for treating type 2 diabetes, showcasing significant differentiation and multi-effect advantages [1][2]. Product Development - HTD1801 has successfully completed two Phase III clinical trials for type 2 diabetes patients in China, with data readouts completed and a head-to-head trial against Dapagliflozin expected to be announced by December 2025 [2]. - The product is in the final sprint of development and is anticipated to enter the New Drug Application (NDA) stage by the end of 2025 [2]. Product Features and Market Potential - HTD1801 is a globally innovative oral anti-inflammatory and metabolic modulator, granted two Fast Track designations by the FDA, and operates through a unique dual mechanism that activates AMPK and inhibits NLRP3 [3]. - The product shows broad efficacy in improving blood glucose metabolism, kidney protection, heart protection, liver protection, anti-inflammation, and weight loss, distinguishing it from other diabetes treatments [3]. - There is a significant unmet clinical need in the treatment of cardio-renal metabolic (CKM) diseases, and HTD1801 has the potential to become a cornerstone therapy in this area, indicating a vast market opportunity [3]. Clinical Trial Results - Phase III clinical data indicates that HTD1801 can significantly and clinically meaningfully reduce HbA1c levels by -1.1% to -1.3%, effectively lowering fasting and postprandial blood glucose levels and improving insulin resistance [4]. - HTD1801 demonstrates superior HbA1c reduction compared to Dapagliflozin, with a higher proportion of patients achieving HbA1c < 7% [4]. - The product also shows significant improvements in cardiovascular metabolic indicators such as LDL-C and non-HDL-C compared to Dapagliflozin, highlighting its competitive advantages [4]. Chronic Kidney Disease (CKD) Application - HTD1801 has shown potential in improving eGFR levels in chronic kidney disease (CKD) treatment, with clinical data indicating its ability to improve eGFR changes in early-stage patients [5]. - In patients with mild renal impairment, HTD1801 significantly improved eGFR compared to placebo, suggesting its potential for restoring kidney function [5].